A Study With Pentasa in Patients With Active Crohn's Disease

Summary

The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.

Timeline

Start

2009-04

Primary completion

2010-10

Completion

2010-10

Outcome

Missed primary endpoint

Stopped (Enrollment): “Terminated due to poor recruitment”

registry Mesalazine vs Placebo; p = 0.231; Odds Ratio (OR) 0.212 (95% CI 0.017 to 2.683); Regression, Logistic NCT00862121 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mesalamine	Small molecule	6 g	Oral

Indications